Which Semaglutides Are Approved for Weight Loss?

Last reviewed: June 11, 2026

Last updated: June 11, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a glucagon-like peptide-1 receptor agonist, received FDA approval for weight loss in 2021 and has since become one of the most widely prescribed medications in precision weight management. Understanding which formulations carry official FDA approval and how compounded alternatives compare can help you make an informed decision about your treatment options.

FDA-Approved Semaglutide Medications for Weight Management

The FDA has approved semaglutide under two distinct brand names for chronic weight management: Wegovy (semaglutide injection) and Rybelsus (oral semaglutide). Wegovy received approval in June 2021 for adults with obesity or overweight with at least one weight-related condition, such as high blood pressure or type 2 diabetes. Rybelsus tablets were later approved as an oral alternative for the same patient population. Both medications work by mimicking GLP-1, a hormone that regulates appetite and blood sugar levels.

Clinical trials demonstrated that patients using FDA-approved semaglutide achieved meaningful weight reduction compared to placebo. The STEP trials, which evaluated Wegovy, showed that participants lost an average of 15% of their body weight over 68 weeks—substantially more than those receiving inactive treatment. These results established semaglutide as a clinically significant tool for long-term weight management when combined with lifestyle modifications.

How Compounded Semaglutide Differs from Brand-Name Versions

Compounded semaglutide is prepared by licensed 503A compounding pharmacies and contains the same active pharmaceutical ingredient as brand-name Wegovy, but is not FDA-approved as a finished product. The distinction matters: brand-name medications undergo rigorous FDA review for safety, efficacy, and manufacturing consistency, while compounded versions are regulated under different standards designed to ensure pharmacy quality and sterility. Both approaches deliver the same semaglutide molecule, but compounded medications offer cost savings and flexible dosing options that may appeal to patients seeking personalized treatment.

PlexusDx partners exclusively with licensed 503A compounding pharmacies to source compounded semaglutide injections, never from 503B facilities. This ensures that your medication is prepared under pharmaceutical-grade standards and quality controls. The decision between brand-name and compounded semaglutide should involve your healthcare provider and account for your clinical needs, insurance coverage, and budget.

Semaglutide Dosing and Treatment Schedules

Both FDA-approved and compounded semaglutide are administered as weekly subcutaneous injections, typically starting at 0.25 mg and titrating upward based on tolerability and clinical response. The standard escalation follows a four-week progression at each dose level, with maximum doses reaching 2.4 mg weekly for Wegovy or individualized amounts for compounded formulations. This gradual titration approach reduces gastrointestinal side effects and allows your body to adapt to the medication's effects.

PlexusDx offers compounded semaglutide injection at a flat monthly rate of $149, with your dose able to increase without raising your price—a transparent pricing model that removes financial barriers to dose optimization. This means you can work with your provider to find your therapeutic dose without worrying about escalating costs at each level. HSA and FSA accounts are eligible for payment, making treatment accessible to more patients.

Genetic Factors in Semaglutide Response and Personalization

Individual response to semaglutide varies partly due to genetic differences in GLP-1 receptor function and appetite-regulation pathways. Variations in the GLP1R gene (such as rs6923761) and other peptide-pathway markers influence how effectively your body responds to GLP-1 agonists and how likely you are to experience nausea or other side effects. Understanding your genetic profile can help your provider tailor semaglutide dosing and anticipate your individual tolerance pattern.

PlexusDx offers the Precision Peptide Genetic Test, a peptide-pathway analysis that maps 14 pathways, 49 peptides, and 150+ genetic insights relevant to weight loss medication response. This test identifies variants in GLP1R, GIPR, FTO, MC4R, and other key genes that predict your likelihood of responding optimally to semaglutide or benefit from combination approaches. Available as a $99 add-on after your first month of treatment, the genetic test can guide long-term personalization of your weight management plan.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as effective as FDA-approved Wegovy?

Compounded semaglutide contains the identical active ingredient as Wegovy and works through the same biological mechanism. Efficacy depends on dose, adherence, and individual genetic factors rather than whether the medication is brand-name or compounded. PlexusDx's compounded semaglutide from licensed 503A pharmacies meets pharmaceutical quality standards and is used by thousands of patients successfully managing their weight.

How quickly does semaglutide produce weight loss results?

Most patients begin noticing appetite suppression and modest weight changes within 2-4 weeks of starting semaglutide. Meaningful weight loss typically accelerates over 8-12 weeks as your dose increases and your body adapts. Clinical trials showed average losses of 5-15% of body weight within three to four months, with continued benefits through 12-16 months of consistent use.

Can I get semaglutide through PlexusDx without insurance?

Yes. PlexusDx serves all 50 states with no insurance requirement, no membership fee, and no prior authorization needed. Semaglutide injection starts at $149 per month and is eligible for HSA and FSA payment, making it accessible regardless of your coverage status. This direct-to-patient model removes insurance barriers that often delay or prevent access to weight loss treatment.

What are the common side effects of semaglutide?

The most frequent side effects are gastrointestinal: nausea, vomiting, constipation, and diarrhea—usually mild and temporary during dose escalation. Rare but serious risks include pancreatitis and gallbladder complications. Your PlexusDx provider will monitor your response at each dose level and can adjust your escalation timeline if side effects are bothersome. Genetic testing may help predict your individual side-effect risk.

Does the Precision Peptide Genetic Test predict how I'll respond to semaglutide?

The Precision Peptide Genetic Test identifies variations in GLP1R, GIPR, FTO, MC4R, and 10+ additional pathways that influence your weight regulation and medication response. Variants in GLP1R (rs6923761) and GIPR (rs1800437) directly affect how your body responds to semaglutide, helping your provider optimize your starting dose and escalation schedule. Available for $99 after your first month, the test refines your personalized treatment approach.

Related Reading

• Maxlife Weight Loss
• Remedy Meds Weight Loss
• Form Health Weight Loss
• Maximus Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.